Vector Development
Non-viral vectors offer a safe approach to long-term gene expression
Published in Gene Therapy Weekly, May 26th, 2005
According to a report from Australia, "the potential dangers of using viruses to deliver and integrate DNA into host cells in gene therapy have been poignantly highlighted in recent clinical trials. Safer, non-viral gene delivery approaches have been largely ignored in the past because of their inefficient delivery and the resulting transient transgene expression. However, recent advances indicate that efficient, long-term gene expression can be achieved by non-viral means."
"In particular, integration of DNA can be targeted to specific genomic sites without deleterious...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-05-26)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Tumor vessel targeting by interferon gamma triggers antitumor activity - Gene Silencing
STAT3 knockdown shutters breast tumor formation in murine models - Liver Cancer
Antiangiogenic gene therapy treats tumors in hepatocellular carcinoma models - Neuroscience
Genetically modified olfactory-derived cells regenerate corticospinal axons - Oncology
The PDX-1 gene is an early marker for a variety of human cancers - Antileukemic
Third generation biphosphate YM529 antileukemic - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
